Brian Goodman, CEO of Golden Matrix Group Inc. explains how they stay one step ahead of their rivals. Watch the interview here.

Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Sponsored Content

Pin to quick picksNorman Broadb Regulatory News (NBB)

Share Price Information for Norman Broadb (NBB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.00
Bid: 3.50
Ask: 4.50
Change: 0.00 (0.00%)
Spread: 1.00 (28.571%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 4.00

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

H1 2024 Trading Update

11 Jul 2024 07:00

RNS Number : 9484V
Norman Broadbent PLC
11 July 2024
 

11 July 2024

 

Norman Broadbent plc

("Norman Broadbent" or the "Company")

 

H1 2024 TRADING UPDATE

 

Resilient through challenging market conditions and well-positioned to capitalise on a recovery

 

Norman Broadbent (AIM: NBB), a leading Executive Search and Interim Management firm, is pleased to announce the following unaudited trading update for the six months ended 30 June 2024 ("H1 2024").

 

Financial highlights

·

Net fee income ("NFI") of £4.5m, down 14% from H1 2023 and up 36% on H1 2022

Q2 2024 NFI of £2.3m up 5% on Q1 2024, down 15% on Q2 2023 and up 28% on Q2 2022

·

Underlying EBITDA1 expected to be in the range of £0.1m to £0.15m (H1 2023: £0.27m)

·

Net debt (excluding lease liabilities) of £0.7m after annual bonus payments, a 42% improvement on 30 June 2023

·

Executive Search NFI down 4% on H1 2023

·

Interim Management down 47% on H1 2023 which, although the smallest part of our business, represents 67% of the drop in NFI in H1 2024, primarily through a reduction of Fixed Term Contract placements 

·

Number of search mandates secured up 5% on H1 2023, although average fee value per mandate was down 9%, reflecting industry-wide trends, particularly in the UK

·

£0.1m bad debt provision taken due to clients facing business challenges, some of which may be recoverable

 

[1] Underlying EBITDA excludes share based payment charges

 

Norman Broadbent expects to announce its unaudited interim results for H1 2024 in early September 2024.

 

Kevin Davidson, CEO of Norman Broadbent, commented:

 

"Growth is rarely linear quarter to quarter, but there is no doubt that, as is the case across the entire executive search and staffing industries, we are navigating extremely challenging market conditions. However, this doesn't impact the confidence we have in our prospects. Therefore, while having been cost conscious in H1 2024, we have continued to invest, growing and upgrading headcount to ensure that the Company is well positioned to capitalise on the recovery when it comes. 

 

Consistent with our long-term growth ambitions, we are actively exploring synergistic acquisition opportunities and pursuing high-quality hiring options in the US. With high levels of staff retention, general economic confidence beginning to return, inflation seemingly under control and an overall expectation of an improvement in market conditions in H2 2024, we remain confident in our ability to deliver on our target of £1.25 million EBITDA by 2025."

 

 

Contacts: 

 

Norman Broadbent plc 

+44 (0)20 7484 0000

Kevin Davidson, CEO 

Mehr Malik, CFO

 

Shore Capital (Nominated Adviser and Broker)  

 

+44 (0)20 7408 4090

Tom Griffiths / Tom Knibbs (Corporate Advisory)

Henry Willcocks (Corporate Broking)

 

Alma (Financial Communications Adviser)

   +44 (0)20 3405 0205

Rebecca Sanders-Hewett

normanbroadbent@almastrategic.com

Kinvara Verdon

David Ison

  

About Norman Broadbent:

 

Norman Broadbent (AIM: NBB) is a professional services firm focused on executive search, senior interim management solutions and bespoke leadership advisory services working across the UK and internationally. ​ 

Established as the first UK-headquartered search firm in 1979, the firm has a 40+ year track record of shaping leadership across industries including Consumer, Financial Services, Industrials, Life Sciences, Investor and TMT.

 

www.normanbroadbent.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTQKKBKCBKDBOD
Date   Source Headline
16th Oct 20247:00 amRNSQ3 2024 Trading Update
11th Oct 20244:00 pmRNSDirector/PDMR shareholding
8th Oct 20247:00 amRNSDirector/PDMR Shareholding
3rd Oct 20247:00 amRNSChange of Registered Office
9th Sep 20247:00 amRNSInterim Results
19th Aug 20247:00 amRNSNotice of Interim Results & Investor Presentation
22nd Jul 20243:46 pmRNSNotification of major holdings
11th Jul 20247:00 amRNSH1 2024 Trading Update
23rd May 20245:29 pmRNSResult of Annual General Meeting
25th Apr 20247:00 amRNSQ1 2024 Trading Update
24th Apr 20247:00 amRNSSmall Cap Awards nomination
15th Apr 20243:18 pmRNSNotification of major holdings
8th Apr 202412:11 pmRNSIssue of Equity and Total Voting Rights
3rd Apr 20244:01 pmRNSNotification of major holdings
28th Mar 20247:00 amRNSPosting of ARA & Notice of AGM
27th Mar 20247:00 amRNSFinal Results
26th Mar 20244:07 pmRNSNotification of major holdings
20th Mar 20241:36 pmRNSNotice of Results & Investor Presentation
18th Mar 20244:33 pmRNSNotification of major holdings
18th Mar 20244:04 pmRNSNotification of major holdings
12th Mar 20243:33 pmRNSAIM Rule 17 Schedule Two (g) Update
22nd Jan 20245:32 pmRNSNotification of Major Holdings
16th Jan 20247:00 amRNSTrading Update
21st Nov 202310:06 amRNSNotification of Major Holdings
20th Nov 202310:45 amRNSDirector/PDMR shareholding
15th Nov 20239:54 amRNSNotification of Major Holdings
15th Nov 20239:43 amRNSNotification of Major Holdings
10th Nov 20237:00 amRNSDirector/PCA Dealing
9th Nov 20232:25 pmRNSDirector/PDMR Shareholding
2nd Nov 20238:43 amRNSConversion Of Outstanding Convertible Loan Notes
12th Oct 20237:00 amRNSQ3 2023 Trading Update
10th Oct 202311:03 amRNSNotification of Major Holdings
9th Oct 20237:00 amRNSSurrender and Granting of Options
28th Jul 20237:00 amRNSGrant of Options
24th Jul 20237:00 amRNSInterim Results
11th Jul 20237:00 amRNSH1 2023 Trading Update
30th Jun 20237:00 amRNSSAYE Option Plan & Director Holding
29th Jun 20234:28 pmRNSResult of AGM
5th Jun 20237:00 amRNSPosting of Annual Report and Notice of AGM
1st Jun 20237:00 amRNSDirectorate changes
31st May 20237:00 amRNSFinal Results
22nd May 20237:00 amRNSQ1 2023 Trading Update
19th May 202312:55 pmRNSPartial Repayment of Convertible Loan Note
24th Jan 20237:00 amRNSTrading Update
10th Jan 20237:00 amRNSDirectorate Change
17th Nov 20224:42 pmRNSTR-1: Notification of major holdings
14th Nov 20227:00 amRNSIssue of Equity
1st Nov 20227:00 amRNSUpdate and Change of Board role
10th Oct 20225:30 pmRNSTR-1: Notification of major holdings
31st Aug 20227:00 amRNSDirector Share Purchase

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Make Better Investment Decisions

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.